Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sarcoma

1321 - Serum miRNA discriminates treatment-naive localized synovial sarcoma patients from those in follow-up after radical combined therapy (488O)

Date

18 Nov 2017

Session

Sarcoma

Presenters

Hanna Kosela Paterczyk

Citation

Annals of Oncology (2017) 28 (suppl_10): x149-x152. 10.1093/annonc/mdx675

Authors

H. Kosela Paterczyk1, M. Mikula2, A. Paziewska3, M. Kulecka3, J. Kaczmarski2, M. Dabrowska2, A. Kluska2, A. Balabas2, M. Piatkowska2, P. Rutkowski1, J. Ostrowski3

Author affiliations

  • 1 Department Of Soft Tissue/bone Sarcoma And Melanoma, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 2 Department Of Genetics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw/PL
  • 3 Department Of Gastroenterology, Hepatology And Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw/PL
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1321

Background

Synovial sarcoma (SySa) is an aggressive neoplasm that accounts for approximately 10% of all soft-tissue tumors. The levels of miRNAs in blood circulation was investigated in the past for SySa patients with array technology, however to date no exploratory next-generation sequencing (NGS) approach was used to evaluate blood circulating miRNA as response markers of SySa treatment. We present data coming from patients with locally advanced synovial sarcoma treated according to a uniform protocol of preoperative therapy (chemotherapy and radiotherapy).

Methods

Serum samples of 28 SySa patients prior to preoperative therapy, following two courses of neoadjuvant chemotherapy (n = 23) and in follow-up after radical radiotherapy and surgery (n = 18) as well as the serum of healthy 30 donors were collected. MiRNAs were isolated from serum with MirVANA miRNA Isolation Kit and then analyzed using deep sequencing on Ion Torrent PGM. Reads were mapped to miRBase miRNA collection with miRDeep2. Differential expression was evaluated with edgeR. Comparisons were made between samples before treatment and those during treatment, in observation after treatment as well as healthy controls. Separate comparisons were also made for samples before and after surgical treatment.

Results

Deep sequencing identified 1370 miRNAs. 47 miRNAs differentiated (adj. p- value

Conclusions

Our NGS-based approach have identified blood circulating miRNAs with high to good discriminative properties to differentiate treatment-naive and SySa patients after treatment or in observation following the surgery. Further evaluation on an independent group of patients is warranted to confirm their value as a biomarker for the diagnosis of SySa recurrence or metastasis.

Clinical trial identification

Legal entity responsible for the study

Piotr Rutkowski

Funding

National Science Center [2013/11/B/NZ5/03165 to PR]

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.